Updated GADOLIN Study Shows Survival Benefit in Indolent NHL Updated GADOLIN Study Shows Survival Benefit in Indolent NHL

An updated analysis of the GADOLIN study confirms the PFS benefit of obinutuzumab and bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma.Journal of Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news